Kelyniam Corporate Update
Kelyniam Global (KLYG) has announced significant financial achievements for calendar year 2024, including record revenues exceeding $3.3 million, representing at least 25% growth. The company's operating income increased by at least $500,000 compared to 2023.
The company has completed a comprehensive review of legacy and Covid-related matters, which will be reported as Restructuring Costs and Non-cash Compensation in their annual financial statements. Additionally, KLYG is planning to move to the OTCID Basic Market in 2025 and is considering a reverse stock split after their June 2025 shareholders meeting to improve share liquidity.
The company will host an investor presentation on January 29th, 2025, at 2:00 EST in collaboration with GeoInvesting. Kelyniam specializes in rapid production of custom cranial and maxillo-facial prosthetics using advanced medical grade polymers.
Kelyniam Global (KLYG) ha annunciato risultati finanziari significativi per l'anno solare 2024, inclusi ricavi record superiori a 3,3 milioni di dollari, che rappresentano almeno un 25% di crescita. Il reddito operativo dell'azienda è aumentato di almeno 500.000 dollari rispetto al 2023.
L'azienda ha completato una revisione completa delle questioni legate ai legacy e al Covid, che saranno riportate come Costi di Ristrutturazione e Compensazione Non Monetaria nei loro bilanci annuali. Inoltre, KLYG prevede di trasferirsi al Mercato OTCID Basic nel 2025 e sta considerando uno split azionario inverso dopo l'assemblea degli azionisti di giugno 2025 per migliorare la liquidità delle azioni.
L'azienda ospiterà una presentazione per gli investitori il 29 gennaio 2025, alle 14:00 EST, in collaborazione con GeoInvesting. Kelyniam è specializzata nella produzione rapida di protesi craniche e maxillo-facciali su misura utilizzando polimeri di grado medico avanzati.
Kelyniam Global (KLYG) ha anunciado logros financieros significativos para el año calendario 2024, incluyendo ingresos récord que superan los 3.3 millones de dólares, lo que representa al menos un 25% de crecimiento. Los ingresos operativos de la empresa aumentaron en al menos 500,000 dólares en comparación con 2023.
La empresa ha completado una revisión exhaustiva de los asuntos relacionados con el legado y el Covid, que se informarán como Costos de Reestructuración y Compensación No Monetaria en sus estados financieros anuales. Además, KLYG planea trasladarse al Mercado OTCID Basic en 2025 y está considerando un split inverso de acciones después de la reunión de accionistas de junio de 2025 para mejorar la liquidez de las acciones.
La empresa llevará a cabo una presentación para inversores el 29 de enero de 2025, a las 2:00 PM EST, en colaboración con GeoInvesting. Kelyniam se especializa en la producción rápida de prótesis craneales y maxilofaciales personalizadas utilizando polímeros de grado médico avanzado.
Kelyniam Global (KLYG)은 2024년 달력 연도를 위한 중요한 재무 성과를 발표했습니다. 300만 달러를 초과하는 기록적인 수익이 포함되어 있으며, 이는 최소 25% 성장에 해당합니다. 회사의 운영 수익은 2023년과 비교하여 최소 500,000 달러 증가했습니다.
회사는 레거시 및 코로나 관련 사안에 대한 종합적인 검토를 완료하였으며, 이는 연간 재무제표에서 구조조정 비용 및 비현금 보상으로 보고될 예정입니다. 또한 KLYG는 2025년에 OTCID 기본 시장으로 이전할 계획이며, 2025년 6월 주주 회의 이후 주식 유동성을 개선하기 위해 주식 분할을 고려하고 있습니다.
회사는 2025년 1월 29일 EST 오후 2시에 GeoInvesting와 협력하여 투자자 발표를 개최할 예정입니다. Kelyniam은 고급 의료용 폴리머를 사용하여 맞춤형 두부 및 악안면 보철물의 신속한 생산을 전문으로 합니다.
Kelyniam Global (KLYG) a annoncé des résultats financiers significatifs pour l'année civile 2024, y compris des revenus record dépassant 3,3 millions de dollars, représentant une croissance d'au moins 25%. Le revenu opérationnel de l'entreprise a augmenté d'au moins 500 000 dollars par rapport à 2023.
L'entreprise a complété un examen approfondi des questions héritées et liées à la Covid, qui seront rapportées comme Coûts de Restructuration et Compensation Hors Liquidité dans leurs états financiers annuels. De plus, KLYG prévoit de passer au marché OTCID Basic en 2025 et envisage un regroupement d'actions après l'assemblée des actionnaires de juin 2025 pour améliorer la liquidité des actions.
L'entreprise organisera une présentation pour les investisseurs le 29 janvier 2025 à 14h00 EST en collaboration avec GeoInvesting. Kelyniam est spécialisé dans la production rapide de prothèses crâniennes et maxillo-faciales sur mesure en utilisant des polymères de qualité médicale avancés.
Kelyniam Global (KLYG) hat bedeutende finanzielle Erfolge für das Kalenderjahr 2024 angekündigt, darunter rekordhohe Einnahmen von über 3,3 Millionen Dollar, was mindestens einem Wachstum von 25% entspricht. Das Betriebseinkommen des Unternehmens stieg im Vergleich zu 2023 um mindestens 500.000 Dollar.
Das Unternehmen hat eine umfassende Überprüfung von Legacy- und Covid-relatierten Angelegenheiten abgeschlossen, die in ihren Jahresabschlüssen als Umstrukturierungskosten und nicht-monetäre Vergütungen ausgewiesen werden. Darüber hinaus plant KLYG, 2025 in den OTCID Basic Market zu wechseln, und zieht die Durchführung eines Reverse-Stock-Splits nach der Hauptversammlung im Juni 2025 in Betracht, um die Liquidität der Aktien zu verbessern.
Das Unternehmen wird am 29. Januar 2025 um 14:00 EST eine Investorenpräsentation in Zusammenarbeit mit GeoInvesting abhalten. Kelyniam ist auf die schnelle Produktion von maßgeschneiderten cranialen und maxillofazialen Prothesen spezialisiert, die aus hochwertigen medizinischen Polymeren hergestellt werden.
- Record revenue exceeding $3.3 million in 2024
- 25% year-over-year revenue growth
- Operating income increase of at least $500,000 compared to 2023
- Planned upgrade to OTCID Basic Market in 2025
- Potential shareholder dilution from upcoming reverse stock split
- Restructuring costs and non-cash compensation charges to be reported
- Current share price below $1, limiting trading liquidity
A RECORD YEAR FOR KLYG!
- Kelyniam Global will announce calendar year '24 record revenues in excess of
$3.3 million 25% . The Company will report an increased operating income of at least at half million dollars ($500,000 - The Company completed an exhaustive review of legacy and Covid-related costs, assets and obligations and will report several matters outside of continuing operations in its annual financial statements. These matters, the majority of which are non-cash, represent a corporate reset and involve obsolete inventory, disposition of assets, satisfaction of compensatory obligations and a comprehensive review of the balance sheet for stranded assets and obligations. The results of this exercise will be reported as Restructuring Costs and Non-cash Compensation.
- The Company has been notified by its Broker-Dealer marketplace, OTCIQ, that it will be changing the requirements for the exchange where Kelyniam shares are traded. The Company plans to take the necessary steps to qualify for and move to the new OTCID Basic Market in 2025.
- The Company is contemplating a reverse stock split to occur after the annual shareholders meeting in late June 2025. The Company is undertaking this effort to provide our shareholders with additional depository and liquidity opportunities not currently available due to the current share price offering of less than
$1 - On January 29th, 2:00 EST, the Company will be conducting an investor presentation at the invitation of GeoInvesting.(www.Geoinvesting.com). The discussion will reference a company slide presentation and will be held in a fireside chat format. Access to the presentation is provided by GeoInvesting. The meeting invitation materials can be found at the following registration link:
https://us02web.zoom.us/meeting/register/vZE43p_zSw-_ZjY47nvETQ
"Kelyniam left 2024 with strong momentum and we are excited about the prospects for the business in 2025," said Bjella.
Other information regarding the Company can be found on the company's website at www.Kelyniam.com.
Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients. Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam's web site address is www.Kelyniam.com.
As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; and changes in the status of ability to market products.
View original content:https://www.prnewswire.com/news-releases/kelyniam-corporate-update-302355673.html
SOURCE Kelyniam Global Inc
FAQ
What is Kelyniam's (KLYG) revenue growth for 2024?
When is KLYG planning to implement the reverse stock split in 2025?
What was KLYG's operating income increase in 2024?
When will KLYG move to the OTCID Basic Market?
When is Kelyniam's (KLYG) investor presentation with GeoInvesting?
